[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-001", "question": "A 45-year-old man with autosomal dominant polycystic kidney disease presents with acute flank pain and hematuria. Imaging reveals a 6 cm cyst with internal septations and hemorrhage. Renal function is preserved, but he develops fever and leukocytosis. Blood cultures are negative, but cyst aspiration yields purulent fluid positive for Escherichia coli. Despite appropriate intravenous antibiotics, his symptoms persist. What is the most appropriate next step in management?", "options": ["Switch to a different antibiotic based on sensitivity testing", "Perform percutaneous cyst drainage and sclerotherapy", "Initiate long-term suppressive antibiotic therapy", "Surgical decortication of the infected cyst", "Administer intraparenchymal antibiotic infusion"], "answer": "D", "answer_index": 3, "explanation": "Surgical decortication is indicated for persistent cyst infection in polycystic kidney disease when antibiotics and drainage fail, as it allows complete removal of infected material. Percutaneous drainage often fails due to viscous cyst contents and multiloculation, while sclerotherapy is not appropriate for infected cysts. Long-term suppression or antibiotic switches do not address the source of ongoing infection.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: ADPKD patient with acute flank pain, hematuria, 6 cm septated hemorrhagic cyst, fever, leukocytosis, negative blood cultures, purulent cyst aspiration positive for E. coli, preserved renal function, and persistent symptoms despite appropriate IV antibiotics. These indicate an infected complex cyst unresponsive to initial management, pointing to need for definitive intervention. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions, supporting D as uniquely best due to cyst complexity (septations, hemorrhage) making less invasive options inadequate. Main medical accuracy issue(s), if any: Mostly aligns with guidelines (e.g., UpToDate recommends drainage if antibiotics fail; surgery for refractory cases in ADPKD due to viscous/multiloculated cysts), but minor nuance: stem's 'cyst aspiration' is diagnostic, not full therapeutic drainage, so ideally percutaneous catheter drainage should precede surgery, though options limit this (B includes inappropriate sclerotherapy). Overall board-relevant and sensible. Minimal fix: Revise stem to add 'despite percutaneous catheter drainage' after 'antibiotics' to explicitly indicate failure of initial drainage and strengthen defensibility of surgical step.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: ADPKD patient with acute flank pain, hematuria, 6 cm septated hemorrhagic cyst, fever, leukocytosis, negative blood cultures, purulent cyst aspiration positive for E. coli, preserved renal function, and persistent symptoms despite appropriate IV antibiotics. These indicate an infected complex cyst unresponsive to initial management, pointing to need for definitive intervention. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions, supporting D as uniquely best due to cyst complexity (septations, hemorrhage) making less invasive options inadequate. Main medical accuracy issue(s), if any: Mostly aligns with guidelines (e.g., UpToDate recommends drainage if antibiotics fail; surgery for refractory cases in ADPKD due to viscous/multiloculated cysts), but minor nuance: stem's 'cyst aspiration' is diagnostic, not full therapeutic drainage, so ideally percutaneous catheter drainage should precede surgery, though options limit this (B includes inappropriate sclerotherapy). Overall board-relevant and sensible. Minimal fix: Revise stem to add 'despite percutaneous catheter drainage' after 'antibiotics' to explicitly indicate failure of initial drainage and strengthen defensibility of surgical step.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-002", "question": "A 62-year-old woman with chronic lymphocytic leukemia develops petechiae and easy bruising. Laboratory studies show hemoglobin 9.2 g/dL, platelets 12,000/μL, and white blood cells 45,000/μL with 80% lymphocytes. Bone marrow biopsy reveals 90% infiltration by small lymphocytes. She has no active infection or bleeding. What is the most likely mechanism underlying her thrombocytopenia?", "options": ["Autoimmune destruction mediated by anti-platelet antibodies", "Bone marrow suppression from leukemic infiltration", "Hypersplenism with platelet sequestration", "Drug-induced thrombocytopenia from prior chemotherapy", "Microangiopathic hemolytic anemia with consumptive thrombocytopenia"], "answer": "B", "answer_index": 1, "explanation": "In advanced chronic lymphocytic leukemia, thrombocytopenia is primarily due to bone marrow infiltration by leukemic cells, crowding out normal hematopoiesis. Autoimmune thrombocytopenia occurs in only 1-2% of cases and typically responds to steroids, while hypersplenism is less common without massive splenomegaly. Drug effects or microangiopathy are not supported by the clinical scenario.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include bone marrow biopsy showing 90% infiltration by small lymphocytes in a patient with chronic lymphocytic leukemia (CLL), presenting with thrombocytopenia (12,000/μL), anemia (9.2 g/dL), lymphocytosis (80% lymphocytes), petechiae, easy bruising, and absence of active infection, bleeding, splenomegaly, prior chemotherapy, or signs of microangiopathy. These findings strongly support bone marrow suppression from leukemic infiltration as the primary mechanism, making B the unique best choice. Alternatives are inferior: A (autoimmune) lacks evidence of antibodies and is rare in CLL; C (hypersplenism) requires unmentioned splenomegaly; D (drug-induced) has no chemotherapy history; E (microangiopathic) lacks hemolytic features like schistocytes. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing clear differentiation of options. Main medical accuracy issue(s): None; the item's logic aligns with standard hematology knowledge that advanced CLL commonly causes cytopenias via marrow infiltration, per guidelines like NCCN, with autoimmune phenomena being less frequent (1-2%) and other options not supported. Minimal fix: No edit needed; the item is already unambiguous and accurate, though optionally adding 'no splenomegaly' explicitly could reinforce against hypersplenism misinterpretation.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include bone marrow biopsy showing 90% infiltration by small lymphocytes in a patient with chronic lymphocytic leukemia (CLL), presenting with thrombocytopenia (12,000/μL), anemia (9.2 g/dL), lymphocytosis (80% lymphocytes), petechiae, easy bruising, and absence of active infection, bleeding, splenomegaly, prior chemotherapy, or signs of microangiopathy. These findings strongly support bone marrow suppression from leukemic infiltration as the primary mechanism, making B the unique best choice. Alternatives are inferior: A (autoimmune) lacks evidence of antibodies and is rare in CLL; C (hypersplenism) requires unmentioned splenomegaly; D (drug-induced) has no chemotherapy history; E (microangiopathic) lacks hemolytic features like schistocytes. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing clear differentiation of options. Main medical accuracy issue(s): None; the item's logic aligns with standard hematology knowledge that advanced CLL commonly causes cytopenias via marrow infiltration, per guidelines like NCCN, with autoimmune phenomena being less frequent (1-2%) and other options not supported. Minimal fix: No edit needed; the item is already unambiguous and accurate, though optionally adding 'no splenomegaly' explicitly could reinforce against hypersplenism misinterpretation.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-003", "question": "A 28-year-old man with common variable immunodeficiency presents with recurrent sinopulmonary infections. Immunoglobulin levels show IgG 150 mg/dL, IgA <5 mg/dL, and IgM 20 mg/dL. He has absent responses to protein and polysaccharide vaccines. Genetic testing reveals a heterozygous mutation in the TACI gene. What is the most appropriate long-term management strategy?", "options": ["Monthly intravenous immunoglobulin replacement", "Prophylactic antibiotics with trimethoprim-sulfamethoxazole", "Hematopoietic stem cell transplantation", "Rituximab therapy to deplete B cells", "Interleukin-2 supplementation"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin replacement is the cornerstone of therapy for common variable immunodeficiency to prevent infections by providing passive immunity. Prophylactic antibiotics are adjunctive but not sufficient alone, while transplantation is reserved for severe cases with cellular defects. Rituximab and IL-2 are not standard for this humoral immunodeficiency.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections, profoundly low IgG (150 mg/dL), IgA (<5 mg/dL), IgM (20 mg/dL), absent vaccine responses, and heterozygous TACI mutation, all classic for common variable immunodeficiency (CVID) with humoral defect. These point to immunoglobulin deficiency as the core issue, making monthly intravenous immunoglobulin (IVIG) replacement the most appropriate long-term strategy to provide passive immunity and prevent infections. Alternatives are inferior: B (prophylactic antibiotics) is adjunctive but insufficient alone without antibody replacement; C (hematopoietic stem cell transplantation) is reserved for severe combined defects, not isolated humoral issues; D (rituximab) would exacerbate B-cell depletion in an already antibody-deficient state; E (IL-2) targets cellular immunity, irrelevant here. No main logical issues; the vignette is coherent, non-contradictory, and specifies details allowing discrimination of a single best answer without unstated assumptions. No main medical accuracy issues; aligns with current guidelines (e.g., AAAAI, ESID) where IVIG is cornerstone for CVID with recurrent infections and vaccine non-response; TACI mutations are well-associated with CVID. Minimal fix: No edit required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections, profoundly low IgG (150 mg/dL), IgA (<5 mg/dL), IgM (20 mg/dL), absent vaccine responses, and heterozygous TACI mutation, all classic for common variable immunodeficiency (CVID) with humoral defect. These point to immunoglobulin deficiency as the core issue, making monthly intravenous immunoglobulin (IVIG) replacement the most appropriate long-term strategy to provide passive immunity and prevent infections. Alternatives are inferior: B (prophylactic antibiotics) is adjunctive but insufficient alone without antibody replacement; C (hematopoietic stem cell transplantation) is reserved for severe combined defects, not isolated humoral issues; D (rituximab) would exacerbate B-cell depletion in an already antibody-deficient state; E (IL-2) targets cellular immunity, irrelevant here. No main logical issues; the vignette is coherent, non-contradictory, and specifies details allowing discrimination of a single best answer without unstated assumptions. No main medical accuracy issues; aligns with current guidelines (e.g., AAAAI, ESID) where IVIG is cornerstone for CVID with recurrent infections and vaccine non-response; TACI mutations are well-associated with CVID. Minimal fix: No edit required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-004", "question": "A 35-year-old traveler returns from sub-Saharan Africa with fever, chills, and myalgias. Blood smear shows ring forms and gametocytes consistent with Plasmodium falciparum. He is treated with artemether-lumefantrine, but 48 hours later, parasitemia persists at 3%. Genotyping reveals a mutation in the PfKelch13 gene. What is the most appropriate next therapeutic intervention?", "options": ["Switch to atovaquone-proguanil", "Add primaquine for gametocytocidal effect", "Initiate intravenous artesunate", "Administer doxycycline as monotherapy", "Use mefloquine as alternative therapy"], "answer": "C", "answer_index": 2, "explanation": "Persistent parasitemia with PfKelch13 mutation indicates artemisinin resistance, necessitating intravenous artesunate for rapid parasite clearance in severe or resistant falciparum malaria. Atovaquone-proguanil or mefloquine may face cross-resistance, while primaquine and doxycycline are not first-line for acute treatment failure. Artesunate is recommended by WHO for such cases.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include travel from sub-Saharan Africa, symptoms of fever/chills/myalgias, blood smear confirming P. falciparum with ring forms and gametocytes, treatment with artemether-lumefantrine, persistent 3% parasitemia at 48 hours, and PfKelch13 mutation indicating artemisinin resistance. These drive selection of IV artesunate as the next step for rapid clearance in resistant cases. No main logical issues; the vignette provides sufficient details to discriminate a unique best answer without contradictions or underspecification, as persistent high parasitemia post-ACT with confirmed resistance marker supports IV therapy over alternatives that may face cross-resistance or are inappropriate for acute failure. No main medical accuracy issues; aligns with WHO guidelines on artemisinin-resistant P. falciparum, where PfKelch13 mutations correlate with delayed clearance, and IV artesunate is recommended for treatment failure or severe/resistant malaria. Atovaquone-proguanil (A) and mefloquine (E) risk inefficacy in resistant strains; primaquine (B) targets gametocytes but not asexual forms; doxycycline (D) is slow-acting and not monotherapy. Minimal fix: None required; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include travel from sub-Saharan Africa, symptoms of fever/chills/myalgias, blood smear confirming P. falciparum with ring forms and gametocytes, treatment with artemether-lumefantrine, persistent 3% parasitemia at 48 hours, and PfKelch13 mutation indicating artemisinin resistance. These drive selection of IV artesunate as the next step for rapid clearance in resistant cases. No main logical issues; the vignette provides sufficient details to discriminate a unique best answer without contradictions or underspecification, as persistent high parasitemia post-ACT with confirmed resistance marker supports IV therapy over alternatives that may face cross-resistance or are inappropriate for acute failure. No main medical accuracy issues; aligns with WHO guidelines on artemisinin-resistant P. falciparum, where PfKelch13 mutations correlate with delayed clearance, and IV artesunate is recommended for treatment failure or severe/resistant malaria. Atovaquone-proguanil (A) and mefloquine (E) risk inefficacy in resistant strains; primaquine (B) targets gametocytes but not asexual forms; doxycycline (D) is slow-acting and not monotherapy. Minimal fix: None required; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-005", "question": "A 55-year-old man with metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation progresses on osimertinib. Tumor biopsy shows transformation to small cell histology. He has good performance status. What is the most appropriate systemic therapy?", "options": ["Continue osimertinib with added chemotherapy", "Switch to amivantamab", "Initiate etoposide and platinum-based chemotherapy", "Use mobocertinib as targeted therapy", "Administer immune checkpoint inhibitor monotherapy"], "answer": "C", "answer_index": 2, "explanation": "Transformation to small cell lung cancer in EGFR-mutant NSCLC requires treatment as small cell carcinoma with etoposide-platinum chemotherapy, which has shown responses in such cases. Continuing EGFR inhibitors is ineffective post-transformation, while amivantamab and mobocertinib target specific exon 20 insertions but not small cell histology. Immunotherapy has limited efficacy in transformed disease.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic EGFR exon 20 insertion NSCLC progressing on osimertinib, with biopsy-confirmed transformation to small cell histology and good performance status, implying the need for SCLC-directed therapy. The clinical problem asks for the most appropriate systemic therapy post-transformation. Discriminating findings: progression despite targeted therapy, histologic shift to small cell, preserved PS. This implies etoposide-platinum chemotherapy as standard for transformed SCLC. Keyed answer C fits perfectly, aligning with guidelines treating such transformations as de novo SCLC, where EGFR TKIs lose efficacy. Alternatives: A is worse as continuing osimertinib ignores transformation and is ineffective; B and D target EGFR exon 20 but not small cell histology; E has limited efficacy in transformed disease per evidence. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues; rationale matches current NCCN/oncology consensus on SCLC transformation in EGFR-mutant NSCLC, with platinum-etoposide as first-line for good PS patients. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic EGFR exon 20 insertion NSCLC progressing on osimertinib, with biopsy-confirmed transformation to small cell histology and good performance status, implying the need for SCLC-directed therapy. The clinical problem asks for the most appropriate systemic therapy post-transformation. Discriminating findings: progression despite targeted therapy, histologic shift to small cell, preserved PS. This implies etoposide-platinum chemotherapy as standard for transformed SCLC. Keyed answer C fits perfectly, aligning with guidelines treating such transformations as de novo SCLC, where EGFR TKIs lose efficacy. Alternatives: A is worse as continuing osimertinib ignores transformation and is ineffective; B and D target EGFR exon 20 but not small cell histology; E has limited efficacy in transformed disease per evidence. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues; rationale matches current NCCN/oncology consensus on SCLC transformation in EGFR-mutant NSCLC, with platinum-etoposide as first-line for good PS patients. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-006", "question": "A 12-year-old boy with hereditary angioedema type I presents with recurrent abdominal pain and facial swelling. Laboratory studies show C1 inhibitor level 20% of normal and low C4. He has breakthrough episodes despite prophylactic danazol. What is the most appropriate escalation in therapy?", "options": ["Switch to tranexamic acid prophylaxis", "Initiate subcutaneous C1 inhibitor replacement", "Add icatibant for on-demand treatment", "Use ecallantide for acute attacks", "Administer fresh frozen plasma infusions"], "answer": "B", "answer_index": 1, "explanation": "Subcutaneous C1 inhibitor replacement is effective for prophylaxis in hereditary angioedema with breakthrough on androgens, providing targeted replacement of the deficient protein. Tranexamic acid is less effective for type I, while icatibant and ecallantide are for acute treatment, not prophylaxis. Fresh frozen plasma carries risks and is not preferred for long-term use.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 12-year-old with HAE type I (low C1 inhibitor at 20% normal, low C4), recurrent abdominal pain and facial swelling, breakthrough episodes despite prophylactic danazol. These indicate need for escalated prophylaxis targeting the underlying deficiency. The question asks for escalation in therapy, implying improved long-term prevention. Option B (subcutaneous C1 inhibitor replacement) directly addresses C1 inhibitor deficiency and is guideline-recommended for prophylaxis in danazol failures. Alternatives: A (tranexamic acid) is less effective for type I HAE; C (icatibant) and D (ecallantide) are for acute on-demand treatment, not prophylaxis; E (fresh frozen plasma) is for acute attacks and carries infection/allergic risks, unsuitable for escalation. No main logical issues: stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues: aligns with current guidelines (e.g., US HAEA, WAO) favoring C1-INH concentrates for pediatric HAE prophylaxis in breakthrough cases; danazol limitations in children noted. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 12-year-old with HAE type I (low C1 inhibitor at 20% normal, low C4), recurrent abdominal pain and facial swelling, breakthrough episodes despite prophylactic danazol. These indicate need for escalated prophylaxis targeting the underlying deficiency. The question asks for escalation in therapy, implying improved long-term prevention. Option B (subcutaneous C1 inhibitor replacement) directly addresses C1 inhibitor deficiency and is guideline-recommended for prophylaxis in danazol failures. Alternatives: A (tranexamic acid) is less effective for type I HAE; C (icatibant) and D (ecallantide) are for acute on-demand treatment, not prophylaxis; E (fresh frozen plasma) is for acute attacks and carries infection/allergic risks, unsuitable for escalation. No main logical issues: stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues: aligns with current guidelines (e.g., US HAEA, WAO) favoring C1-INH concentrates for pediatric HAE prophylaxis in breakthrough cases; danazol limitations in children noted. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-007", "question": "An 82-year-old woman with mild cognitive impairment presents with recurrent falls and orthostatic hypotension. She takes donepezil 10 mg daily. Autonomic testing shows sympathetic denervation. Brain MRI reveals hippocampal atrophy. What is the most likely underlying diagnosis contributing to her symptoms?", "options": ["Alzheimer disease with autonomic involvement", "Lewy body dementia", "Multiple system atrophy", "Vascular parkinsonism", "Progressive supranuclear palsy"], "answer": "B", "answer_index": 1, "explanation": "Lewy body dementia often presents with orthostatic hypotension due to autonomic dysfunction, recurrent falls, and cognitive impairment with hippocampal atrophy on MRI. Alzheimer disease rarely causes significant autonomic symptoms, while multiple system atrophy typically has more severe parkinsonism and cerebellar signs. Vascular parkinsonism and PSP lack prominent autonomic features.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include mild cognitive impairment, recurrent falls, orthostatic hypotension, sympathetic denervation on autonomic testing, and hippocampal atrophy on MRI, with the patient on donepezil. These support Lewy body dementia (LBD) as the diagnosis, featuring cognitive decline, falls from parkinsonism, and prominent autonomic dysfunction, while hippocampal atrophy can occur though less specifically than in AD. Main logical issues: None; the stem provides sufficient discriminating details to identify B as uniquely best without contradictions or underspecification. Alternatives are inferior: A (AD) lacks typical autonomic involvement; C (MSA) expects severe parkinsonism and cerebellar signs, absent here; D (vascular parkinsonism) involves vascular MRI changes, not hippocampal atrophy or autonomic features; E (PSP) features vertical gaze palsy and lacks autonomic prominence. Main medical accuracy issues: None; aligns with consensus that LBD commonly presents with orthostatic hypotension due to sympathetic denervation, recurrent falls, and cognitive impairment, distinguishing it from AD despite overlapping hippocampal findings. Donepezil use is appropriate for LBD. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include mild cognitive impairment, recurrent falls, orthostatic hypotension, sympathetic denervation on autonomic testing, and hippocampal atrophy on MRI, with the patient on donepezil. These support Lewy body dementia (LBD) as the diagnosis, featuring cognitive decline, falls from parkinsonism, and prominent autonomic dysfunction, while hippocampal atrophy can occur though less specifically than in AD. Main logical issues: None; the stem provides sufficient discriminating details to identify B as uniquely best without contradictions or underspecification. Alternatives are inferior: A (AD) lacks typical autonomic involvement; C (MSA) expects severe parkinsonism and cerebellar signs, absent here; D (vascular parkinsonism) involves vascular MRI changes, not hippocampal atrophy or autonomic features; E (PSP) features vertical gaze palsy and lacks autonomic prominence. Main medical accuracy issues: None; aligns with consensus that LBD commonly presents with orthostatic hypotension due to sympathetic denervation, recurrent falls, and cognitive impairment, distinguishing it from AD despite overlapping hippocampal findings. Donepezil use is appropriate for LBD. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-008", "question": "A 58-year-old man with IgA nephropathy and chronic kidney disease stage 4 develops hyperkalemia refractory to dietary restriction and loop diuretics. Serum potassium is 6.8 mEq/L with normal acid-base status. He is not on ACE inhibitors. What is the most appropriate pharmacologic intervention?", "options": ["Initiate sodium polystyrene sulfonate", "Start patiromer therapy", "Administer sodium zirconium cyclosilicate", "Use fludrocortisone acetate", "Prescribe sodium bicarbonate supplementation"], "answer": "D", "answer_index": 3, "explanation": "Fludrocortisone promotes potassium excretion in the distal tubule and is useful for hyperkalemia in hypoaldosteronism-like states in CKD without acidosis. Patiromer and zirconium are binders for chronic management but less effective in advanced CKD without dialysis. Polystyrene sulfonate has safety concerns, and bicarbonate is for acidotic states.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues include CKD stage 4 from IgA nephropathy, refractory hyperkalemia (6.8 mEq/L) despite diet and loop diuretics, normal acid-base status, and no ACE inhibitors, implying need for additional pharmacologic management without acidosis or drug-induced causes. Main logical issues: The stem is underspecified, lacking details like aldosterone levels, blood pressure, edema status, or ECG changes, allowing multiple defensible options—B (patiromer) and C (sodium zirconium cyclosilicate) as standard chronic binders, and D (fludrocortisone) if assuming unstated hypoaldosteronism; this leads to M where B, C, and D are near-equally reasonable without further discrimination. Option A has known risks but could be acute, while E is irrelevant without acidosis. Main medical accuracy issues: Keyed answer D assumes hypoaldosteronism-like state not supported by stem; rationale inaccurately claims binders are less effective in advanced CKD without dialysis, contradicting guidelines (e.g., KDIGO) where patiromer/SZC are recommended for non-dialysis CKD hyperkalemia, while fludrocortisone risks sodium retention/hypertension in CKD and is reserved for confirmed hypoaldosteronism. Minimal fix: Add to stem 'with low plasma renin and aldosterone levels' to specify type 4 RTA, making D uniquely best and aligning with accuracy.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues include CKD stage 4 from IgA nephropathy, refractory hyperkalemia (6.8 mEq/L) despite diet and loop diuretics, normal acid-base status, and no ACE inhibitors, implying need for additional pharmacologic management without acidosis or drug-induced causes. Main logical issues: The stem is underspecified, lacking details like aldosterone levels, blood pressure, edema status, or ECG changes, allowing multiple defensible options—B (patiromer) and C (sodium zirconium cyclosilicate) as standard chronic binders, and D (fludrocortisone) if assuming unstated hypoaldosteronism; this leads to M where B, C, and D are near-equally reasonable without further discrimination. Option A has known risks but could be acute, while E is irrelevant without acidosis. Main medical accuracy issues: Keyed answer D assumes hypoaldosteronism-like state not supported by stem; rationale inaccurately claims binders are less effective in advanced CKD without dialysis, contradicting guidelines (e.g., KDIGO) where patiromer/SZC are recommended for non-dialysis CKD hyperkalemia, while fludrocortisone risks sodium retention/hypertension in CKD and is reserved for confirmed hypoaldosteronism. Minimal fix: Add to stem 'with low plasma renin and aldosterone levels' to specify type 4 RTA, making D uniquely best and aligning with accuracy.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-009", "question": "A 40-year-old woman with sickle cell disease presents with acute chest syndrome. She has hypoxia, fever, and new infiltrates on chest X-ray. Hemoglobin is 6.5 g/dL, reticulocytes 12%. Transfusion is initiated, but she develops worsening dyspnea and hypertension. What is the most likely complication?", "options": ["Transfusion-related acute lung injury", "Hyperhemolysis syndrome", "Transfusion-associated circulatory overload", "Delayed hemolytic transfusion reaction", "Acute hemolytic reaction from alloantibodies"], "answer": "C", "answer_index": 2, "explanation": "Transfusion-associated circulatory overload is common in sickle cell patients with acute chest syndrome due to volume sensitivity and underlying cardiac strain, presenting with hypertension and dyspnea. TRALI typically involves hypotension, while hyperhemolysis shows hemolysis without volume overload. Delayed reactions occur later, and acute hemolysis presents with fever and back pain.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include SCD with ACS (hypoxia, fever, infiltrates), severe anemia (Hb 6.5 g/dL, retic 12%), and post-transfusion worsening dyspnea and hypertension, pointing to volume overload in a sensitive population. The clinical problem asks for the most likely transfusion complication in this setting, with findings implying TACO due to cardiac strain and volume sensitivity in SCD. Keyed answer C (TACO) fits perfectly, as it explains hypertension and dyspnea without requiring assumptions. Alternatives: A (TRALI) is worse due to typical hypotension, not hypertension; B (hyperhemolysis) lacks evidence of ongoing hemolysis beyond baseline; D (delayed HTR) is untimely as symptoms are acute; E (acute hemolytic) typically involves fever, back pain, and hemolysis signs, not primarily hypertension. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines recognizing TACO risk in SCD/ACS, distinguishing from TRALI by hypertension. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include SCD with ACS (hypoxia, fever, infiltrates), severe anemia (Hb 6.5 g/dL, retic 12%), and post-transfusion worsening dyspnea and hypertension, pointing to volume overload in a sensitive population. The clinical problem asks for the most likely transfusion complication in this setting, with findings implying TACO due to cardiac strain and volume sensitivity in SCD. Keyed answer C (TACO) fits perfectly, as it explains hypertension and dyspnea without requiring assumptions. Alternatives: A (TRALI) is worse due to typical hypotension, not hypertension; B (hyperhemolysis) lacks evidence of ongoing hemolysis beyond baseline; D (delayed HTR) is untimely as symptoms are acute; E (acute hemolytic) typically involves fever, back pain, and hemolysis signs, not primarily hypertension. No main logical issues; stem allows clear discrimination without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines recognizing TACO risk in SCD/ACS, distinguishing from TRALI by hypertension. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-010", "question": "A 50-year-old man with rheumatoid arthritis on methotrexate develops pancytopenia. Bone marrow biopsy shows hypocellularity with absent megakaryocytes. Autoantibody testing is negative. Genetic analysis reveals shortened telomeres and a TERT mutation. What is the most appropriate definitive treatment?", "options": ["Switch to alternative immunosuppressive therapy", "Initiate danazol for telomere elongation", "Perform allogeneic hematopoietic stem cell transplant", "Administer eltrombopag as thrombopoietin mimetic", "Use anti-thymocyte globulin with cyclosporine"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic stem cell transplant is curative for dyskeratosis congenita-related aplastic anemia due to telomere biology disorders, addressing the underlying genetic defect. Danazol may stabilize telomeres temporarily but is not definitive, while immunosuppressives like ATG are for acquired aplasia. Eltrombopag stimulates residual marrow but does not correct the genetic issue.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include pancytopenia in a rheumatoid arthritis patient on methotrexate, bone marrow hypocellularity with absent megakaryocytes suggesting aplastic anemia, negative autoantibodies ruling out autoimmune causes, and genetic findings of shortened telomeres with TERT mutation indicating a telomere biology disorder like dyskeratosis congenita. These clues point to a genetic bone marrow failure syndrome rather than solely drug-induced or acquired aplastic anemia, making allogeneic hematopoietic stem cell transplant (C) the definitive curative treatment by addressing the underlying defect. Main logical issue(s): None; the stem provides sufficient discriminating details to identify C as uniquely best without contradictions or underspecification. Alternatives are inferior: A assumes purely immunosuppressive etiology; B offers temporary telomere stabilization; D provides supportive thrombopoiesis; E targets acquired immune-mediated aplasia. Main medical accuracy issue(s): None; aligns with current guidelines where HSCT is standard for eligible patients with telomere disorders causing aplastic anemia, while others are palliative or inappropriate. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include pancytopenia in a rheumatoid arthritis patient on methotrexate, bone marrow hypocellularity with absent megakaryocytes suggesting aplastic anemia, negative autoantibodies ruling out autoimmune causes, and genetic findings of shortened telomeres with TERT mutation indicating a telomere biology disorder like dyskeratosis congenita. These clues point to a genetic bone marrow failure syndrome rather than solely drug-induced or acquired aplastic anemia, making allogeneic hematopoietic stem cell transplant (C) the definitive curative treatment by addressing the underlying defect. Main logical issue(s): None; the stem provides sufficient discriminating details to identify C as uniquely best without contradictions or underspecification. Alternatives are inferior: A assumes purely immunosuppressive etiology; B offers temporary telomere stabilization; D provides supportive thrombopoiesis; E targets acquired immune-mediated aplasia. Main medical accuracy issue(s): None; aligns with current guidelines where HSCT is standard for eligible patients with telomere disorders causing aplastic anemia, while others are palliative or inappropriate. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-011", "question": "A 25-year-old man with HIV on antiretroviral therapy presents with headache and seizures. CSF analysis shows lymphocytic pleocytosis, elevated protein, and positive India ink stain. MRI reveals multiple ring-enhancing lesions. CD4 count is 150 cells/μL. What is the most appropriate initial management?", "options": ["Start amphotericin B and flucytosine induction", "Initiate pyrimethamine and sulfadiazine", "Administer acyclovir for herpes encephalitis", "Use intravenous ceftriaxone for bacterial meningitis", "Prescribe albendazole for neurocysticercosis"], "answer": "A", "answer_index": 0, "explanation": "Cryptococcal meningitis in HIV presents with India ink-positive CSF and ring-enhancing lesions, requiring induction with amphotericin B and flucytosine for clearance. Toxoplasmosis lacks India ink positivity, while herpes, bacterial, and parasitic etiologies do not match the CSF findings. Prompt antifungal therapy reduces mortality in this setting.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: HIV with CD4 150, headache/seizures, CSF lymphocytic pleocytosis/elevated protein/positive India ink stain (pathognomonic for Cryptococcus), MRI multiple ring-enhancing lesions. These point to cryptococcal meningitis, making amphotericin B + flucytosine induction the best initial management. Alternatives are inferior: B (pyrimethamine/sulfadiazine) fits toxoplasmosis but lacks India ink positivity; C (acyclovir) mismatches non-viral CSF; D (ceftriaxone) suits bacterial but not lymphocytic profile; E (albendazole) for cysticercosis ignores HIV context and India ink.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating details for unique best answer without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with IDSA guidelines for cryptococcal meningitis in HIV, emphasizing prompt antifungal induction to reduce mortality. Ring-enhancing lesions are consistent, though not exclusive, but India ink specificity resolves differential.\\nMinimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: HIV with CD4 150, headache/seizures, CSF lymphocytic pleocytosis/elevated protein/positive India ink stain (pathognomonic for Cryptococcus), MRI multiple ring-enhancing lesions. These point to cryptococcal meningitis, making amphotericin B + flucytosine induction the best initial management. Alternatives are inferior: B (pyrimethamine/sulfadiazine) fits toxoplasmosis but lacks India ink positivity; C (acyclovir) mismatches non-viral CSF; D (ceftriaxone) suits bacterial but not lymphocytic profile; E (albendazole) for cysticercosis ignores HIV context and India ink.\nMain logical issue(s), if any: None; stem provides sufficient discriminating details for unique best answer without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with IDSA guidelines for cryptococcal meningitis in HIV, emphasizing prompt antifungal induction to reduce mortality. Ring-enhancing lesions are consistent, though not exclusive, but India ink specificity resolves differential.\nMinimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-012", "question": "A 65-year-old woman with triple-negative breast cancer metastatic to liver and bones receives paclitaxel. After the third cycle, she develops grade 3 neuropathy and pancytopenia. Germline testing reveals a PALB2 mutation. What is the most appropriate adjustment to her treatment regimen?", "options": ["Switch to eribulin monotherapy", "Add olaparib as PARP inhibitor", "Initiate sacituzumab govitecan", "Use capecitabine as oral chemotherapy", "Administer talazoparib with dose reduction"], "answer": "B", "answer_index": 1, "explanation": "PALB2 mutations confer sensitivity to PARP inhibitors like olaparib in metastatic breast cancer, offering a targeted approach after chemotherapy toxicity. Eribulin and capecitabine are chemotherapies without targeting the mutation, while sacituzumab is for later lines. Talazoparib is another PARP but not first-choice here.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (primary), U (secondary). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 65-year-old with metastatic triple-negative breast cancer (liver, bones), developing grade 3 neuropathy and pancytopenia after third cycle of paclitaxel, with germline PALB2 mutation; question seeks most appropriate regimen adjustment. These clues suggest need for targeted therapy due to PALB2 (HRR gene conferring PARP sensitivity) amid chemo toxicity, but lack details on prior lines of therapy. Main logical issue(s): Multiple answers defensible—B (olaparib) and E (talazoparib) both target PALB2 via PARP inhibition with similar evidence; C (sacituzumab govitecan) could be if assuming ≥2 prior therapies (not stated), creating ties; underspecified prior treatment history requires assumptions for eligibility (e.g., PARP post-chemo, sacituzumab post-2 lines). Main medical accuracy issue(s): Accurate per NCCN guidelines recommending PARP inhibitors (olaparib or talazoparib) for germline PALB2 in metastatic breast cancer; however, no clear preference for olaparib over talazoparib, and 'add' olaparib phrasing implies combination despite toxicity, which is nonstandard. Minimal fix: Revise stem to specify 'after anthracycline and taxane in metastatic setting' and change option B to 'Switch to olaparib monotherapy' to eliminate ambiguity and ensure unique best (B).\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (primary), U (secondary). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: 65-year-old with metastatic triple-negative breast cancer (liver, bones), developing grade 3 neuropathy and pancytopenia after third cycle of paclitaxel, with germline PALB2 mutation; question seeks most appropriate regimen adjustment. These clues suggest need for targeted therapy due to PALB2 (HRR gene conferring PARP sensitivity) amid chemo toxicity, but lack details on prior lines of therapy. Main logical issue(s): Multiple answers defensible—B (olaparib) and E (talazoparib) both target PALB2 via PARP inhibition with similar evidence; C (sacituzumab govitecan) could be if assuming ≥2 prior therapies (not stated), creating ties; underspecified prior treatment history requires assumptions for eligibility (e.g., PARP post-chemo, sacituzumab post-2 lines). Main medical accuracy issue(s): Accurate per NCCN guidelines recommending PARP inhibitors (olaparib or talazoparib) for germline PALB2 in metastatic breast cancer; however, no clear preference for olaparib over talazoparib, and 'add' olaparib phrasing implies combination despite toxicity, which is nonstandard. Minimal fix: Revise stem to specify 'after anthracycline and taxane in metastatic setting' and change option B to 'Switch to olaparib monotherapy' to eliminate ambiguity and ensure unique best (B).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-013", "question": "A 4-year-old girl with Wiskott-Aldrich syndrome presents with eczema, thrombocytopenia, and recurrent infections. She has low IgM and elevated IgE. Hematopoietic stem cell transplant is planned, but she develops hives after platelet transfusion. What is the most likely immunologic mechanism?", "options": ["IgA deficiency leading to anti-IgA antibodies", "Type I hypersensitivity to platelet antigens", "Complement activation by immune complexes", "IgE-mediated reaction to plasma proteins", "Delayed T-cell mediated hypersensitivity"], "answer": "D", "answer_index": 3, "explanation": "Elevated IgE in Wiskott-Aldrich syndrome predisposes to allergic reactions, including IgE-mediated hives from plasma proteins in transfusions. IgA deficiency is not typical, while type I hypersensitivity to antigens is less specific. Complement or T-cell mechanisms do not explain acute urticaria.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Wiskott-Aldrich syndrome (WAS) with eczema, thrombocytopenia, recurrent infections, low IgM, elevated IgE; develops hives (acute urticaria) after platelet transfusion. These point to IgE-mediated allergic reaction, common in WAS due to high IgE, with transfusions often triggering responses to plasma proteins. Main logical issue(s), if any: None; stem supports D as unique best, distinguishing from alternatives (A incorrect as WAS features elevated, not deficient IgA; B less precise, as allergic reactions typically target plasma proteins over platelet antigens; C implies Type III, not fitting acute hives; E is Type IV delayed, inconsistent with timing). Main medical accuracy issue(s), if any: None; aligns with standard knowledge—WAS immunoglobulin profile (low IgM, high IgE/IgA) predisposes to atopy/allergies; transfusion urticaria classically IgE-mediated to plasma proteins per AABB/transfusion medicine guidelines; no outdated or erroneous associations. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'unwashed' to platelet transfusion in stem to emphasize plasma presence.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Wiskott-Aldrich syndrome (WAS) with eczema, thrombocytopenia, recurrent infections, low IgM, elevated IgE; develops hives (acute urticaria) after platelet transfusion. These point to IgE-mediated allergic reaction, common in WAS due to high IgE, with transfusions often triggering responses to plasma proteins. Main logical issue(s), if any: None; stem supports D as unique best, distinguishing from alternatives (A incorrect as WAS features elevated, not deficient IgA; B less precise, as allergic reactions typically target plasma proteins over platelet antigens; C implies Type III, not fitting acute hives; E is Type IV delayed, inconsistent with timing). Main medical accuracy issue(s), if any: None; aligns with standard knowledge—WAS immunoglobulin profile (low IgM, high IgE/IgA) predisposes to atopy/allergies; transfusion urticaria classically IgE-mediated to plasma proteins per AABB/transfusion medicine guidelines; no outdated or erroneous associations. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'unwashed' to platelet transfusion in stem to emphasize plasma presence.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-014", "question": "A 78-year-old man with frailty and multimorbidity is admitted for pneumonia. He has a history of recurrent Clostridium difficile infections. Stool testing is positive for toxin. He completed vancomycin taper 2 weeks ago. What is the most appropriate treatment considering his geriatric status?", "options": ["Repeat oral vancomycin course", "Initiate fidaxomicin therapy", "Administer bezlotoxumab infusion", "Perform fecal microbiota transplant", "Use metronidazole as alternative"], "answer": "C", "answer_index": 2, "explanation": "Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, reduces recurrence in high-risk elderly patients without altering gut flora, ideal for frail geriatrics. Fidaxomicin is effective but costly, while repeat vancomycin increases resistance risk. Transplant is invasive, and metronidazole is inferior for recurrences.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (primary; multiple answers defensible), secondary U (underspecified on symptom severity and exact recurrence count).\\nVerdict on keyed answer: Miskeyed / Not uniquely determinable.\\nKey stem clues that drive (or fail to drive) a unique best answer: 78-year-old frail man with multimorbidity, admitted for pneumonia, history of recurrent C. difficile infections, positive stool toxin, completed vancomycin taper 2 weeks ago; clues suggest high-risk recurrent CDI but lack details on current symptoms (e.g., diarrhea) or precise recurrence number, failing to pinpoint one best option.\\nMain logical issue(s): Multiple options defensible—A (repeat vancomycin, standard for first recurrence), B (fidaxomicin, preferred for recurrence prevention in high-risk patients), D (FMT, indicated for multiple recurrences)—creating ties without stem details to discriminate; underspecification requires assumptions about CDI activity and history to select uniquely.\\nMain medical accuracy issue(s): Keyed C (bezlotoxumab) inaccurately implies standalone treatment, but IDSA guidelines require it as adjunct to antibiotics (e.g., with fidaxomicin/vancomycin) for recurrence prevention in high-risk elderly; rationale misleads by omitting this, overstates vancomycin resistance risk, and presents metronidazole as alternative despite it being non-recommended for CDI.\\nMinimal fix: Revise key to B (fidaxomicin), as it aligns with guidelines for recurrent CDI in geriatrics without needing unstated assumptions.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (primary; multiple answers defensible), secondary U (underspecified on symptom severity and exact recurrence count).\nVerdict on keyed answer: Miskeyed / Not uniquely determinable.\nKey stem clues that drive (or fail to drive) a unique best answer: 78-year-old frail man with multimorbidity, admitted for pneumonia, history of recurrent C. difficile infections, positive stool toxin, completed vancomycin taper 2 weeks ago; clues suggest high-risk recurrent CDI but lack details on current symptoms (e.g., diarrhea) or precise recurrence number, failing to pinpoint one best option.\nMain logical issue(s): Multiple options defensible—A (repeat vancomycin, standard for first recurrence), B (fidaxomicin, preferred for recurrence prevention in high-risk patients), D (FMT, indicated for multiple recurrences)—creating ties without stem details to discriminate; underspecification requires assumptions about CDI activity and history to select uniquely.\nMain medical accuracy issue(s): Keyed C (bezlotoxumab) inaccurately implies standalone treatment, but IDSA guidelines require it as adjunct to antibiotics (e.g., with fidaxomicin/vancomycin) for recurrence prevention in high-risk elderly; rationale misleads by omitting this, overstates vancomycin resistance risk, and presents metronidazole as alternative despite it being non-recommended for CDI.\nMinimal fix: Revise key to B (fidaxomicin), as it aligns with guidelines for recurrent CDI in geriatrics without needing unstated assumptions.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}]